Effect of depression and serotonin reuptake inhibitors antidepressant treatment during pregnancy on protein expression in the human placenta: A quantitative proteomics analysis

ABSTRACT: ## Overview This dataset contains mass spectrometry-based proteomics results from term placenta tissue specimens collected at birth from a cohort of pregnant individuals. The aim was to characterize placental protein expression in relation to maternal depressive symptoms and Selective Serotonin Reuptake Inhibitor (SSRI) treatment during the antenatal period. ## Project Details ### Participants and Sample Stratification Placenta tissue samples were collected from pregnant individuals in metropolitan Vancouver, Canada, as part of an ethically approved observational cohort study (University of British Columbia/Children’s and Women’s Research Ethics Board: H12-00733, H16-02280). Written informed consent was obtained from all participants, and study procedures complied with the Helsinki Declaration (2008 revision). Depressive symptoms were assessed using the Mini International Neuropsychiatric Interview (MINI) and the Hamilton Depression Rating Scale (HAM-D) at recruitment and at 36 weeks gestation. Group assignment was determined as follows: - Symptomatic depression: HAM-D score ≥ 8 at 36 weeks gestation - Control group: HAM-D < 8 and no SSRI treatment - Three groups included: (1) Controls, (2) Mild/moderate depressive symptoms without SSRI, (3) Mild/moderate depressive symptoms with SSRI Participants exposed to SSRIs (fluoxetine, paroxetine, sertraline, citalopram, or escitalopram) received treatment for at least 75 days prior to delivery, with adherence monitored throughout pregnancy. Individuals meeting exclusion criteria (medical/psychiatric conditions other than unipolar depression/anxiety, substance abuse, gestational hypertension, diabetes, placental insufficiency, fetal anomaly, intrauterine growth restriction) were not included. **The final dataset comprises 70 placenta samples

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Placenta

SUBMITTER: Cathy Vaillancourt  

LAB HEAD: Cathy Vaillancourt

PROVIDER: PXD071192 | Pride | 2025-12-22

REPOSITORIES: Pride